Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C1864663 (
HCC
)
2,985
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Liver-specific deletion of autophagy-related genes in mice leads to hepatomegaly, liver injury and spontaneous liver tumorigenesis. Accumulating evidence indicates that p62/SQSTM1-mediated NFE2L2/Nrf2/(nuclear factor, erythroid 2 like 2) activation plays a critical role in promoting liver injury and tumorigenesis in autophagy-defective livers. However, the mechanisms of how persistent NFE2L2 activation induces liver injury and tumorigenesis are unknown. In a recent study, it was found that deletion of
Mtor
(mechanistic target of rapamycin kinase) or
Rptor/Raptor
attenuates hepatomegaly and liver injury in young liver-specific
atg5
knockout mice but accelerates liver tumorigenesis in old mice likely due to feedback AKT activation. Overall, these findings suggest that both hyper- and hypo-activation of MTOR are detrimental to the liver resulting in the development of liver tumors. A balanced MTOR activity is critical to maintain the normal physiological functions of the liver, and caution should be exercised when treating hepatocellular carcinomas using MTOR inhibitors.
Abbreviations:
Atg5: autophgy related 5; DKO: double-knockout;
HCC
: hepatocellular carcinoma; INS: insulin; INSR:
insulin receptor
; KEAP1: kelch-like ECH-associated protein 1; KO: knockout; MTOR: mechanistic target of rapamycin kinase; NFE2L2: nuclear factor, erythroid 2 like 2; raptor: regulatory associated protein of MTOR, complex 1; SQSTM1: sequestosome 1: tsc1: TSC complex subunit 1.
...
PMID:The double-edged sword of MTOR in autophagy deficiency induced-liver injury and tumorigenesis. 3121 56
Rationale:
Ascorbate is an essential micronutrient known for redox functions at normal physiologic concentrations. In recent decades, pharmacological ascorbate has been found to selectively kill tumour cells. However, the dosing frequency of pharmacologic ascorbate in humans has not yet been defined.
Methods:
We determined that among five hepatic cell lines, Huh-7 cells were the most sensitive to ascorbate. The effects of high-dose ascorbate on hepatoma were therefore assessed using Huh-7 cells and xenograft tumour mouse model.
Results:
In Huh-7 cells, ascorbate induced a significant increase in the percentage of cells in the
G0/G1
phase, apoptosis and intracellular levels of ROS. High doses of ascorbate (4.0 pmol cell
-1
), but not low doses of ascorbate (1.0 pmol cell
-1
), also served as a pro-drug that killed hepatoma cells by altering mitochondrial respiration. Furthermore, in a Huh-7 cell xenograft tumour mouse model, intraperitoneal injection of ascorbate (4.0 g/kg/3 days) but not a lower dose of ascorbate (2.0 g/kg/3 days) significantly inhibited tumour growth. Gene array analysis of
HCC
tumour tissue from xenograft mice given IP ascorbate (4.0 g/kg/3 days) identified changes in the transcript levels of 192 genes/ncRNAs involved in
insulin receptor
signalling, metabolism and mitochondrial respiration. Consistent with the array data, gene expression levels of
AGER, DGKK, ASB2, TCP10L2, Lnc-ALCAM-3
, and
Lnc-TGFBR2-1
were increased 2.05-11.35 fold in
HCC
tumour tissue samples from mice treated with high-dose ascorbate, and IHC staining analysis also verified that AGER/RAGE and DGKK proteins were up-regulated, which implied that
AGER/RAGE
and
DGKK
activation might be related to oxidative stress, leading to hepatoma cell death.
Conclusions:
Our studies identified multiple mechanisms are responsible for the anti-tumour activity of ascorbate and suggest high doses of ascorbate with less frequency will act as a novel therapeutic agent for liver cancer
in vivo
.
...
PMID:Hepatomas are exquisitely sensitive to pharmacologic ascorbate (P-AscH
-
). 3175 84